This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Commissariat a L'energie Atomique Et Aux Energies Alternatives, National Institute of Health and Medical Research. Active years: 2014.
Company Filing History:
1 out of 8,807 
1 out of 1,853 
Years Active: 2014
Title: The Innovative Contributions of Mathieu Laramas
Introduction
Mathieu Laramas is a notable inventor based in Meylan, France. He has made significant contributions to the field of medical diagnostics, particularly in the area of prostate cancer. His innovative work has the potential to improve the accuracy of cancer diagnoses and enhance patient outcomes.
Latest Patents
Laramas holds a patent for an in vitro method for diagnosing prostate cancer. This invention relates to a method that utilizes antibodies and fragments directed against CK2-α for the diagnosis and prognosis of prostate cancer. His patent represents a crucial advancement in the early detection of this prevalent disease.
Career Highlights
Throughout his career, Mathieu Laramas has worked with esteemed organizations such as the National Institute of Health and Medical Research and the Commissariat à l'Énergie Atomique. His experience in these institutions has allowed him to develop and refine his innovative ideas, contributing to the advancement of medical research.
Collaborations
Laramas has collaborated with notable colleagues, including Claude Cochet and Odile Filhol. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further enhancing the impact of his work.
Conclusion
Mathieu Laramas is a distinguished inventor whose work in prostate cancer diagnostics exemplifies the importance of innovation in medicine. His contributions have the potential to significantly improve patient care and outcomes in the fight against cancer.